LSE:AZNPharmaceuticals
AstraZeneca Oncology Wins Raise Questions For Long Term Growth Story
AstraZeneca received European Union approval for Imfinzi in certain early-stage gastric cancers, following positive survival data.
The company also secured US FDA Priority Review for Enhertu in HER2 positive early breast cancer.
Both decisions expand AstraZeneca's oncology reach and could influence its long term competitive positioning.
AstraZeneca, ticker LSE:AZN, is adding these regulatory milestones to an already established oncology franchise. The share price stands at £144.02, with the...